DELFI Diagnostics Unveils Blood Test for Enhanced Lung Cancer Screening
DELFI’s blood test provides results by determining the likelihood of detecting lung cancer through low-dose CT, with an NPV of 99.7 percent.
Read MorePosted by Andy Lundin | Oct 10, 2023 | Lung Cancer |
DELFI’s blood test provides results by determining the likelihood of detecting lung cancer through low-dose CT, with an NPV of 99.7 percent.
Read MorePosted by Chris Wolski | Jun 30, 2023 | Lung Cancer |
A blood-based test developed by researchers can predict the risk of dying from lung cancer when combined with a personalized risk model.
Read MorePosted by Melanie Hamilton-Basich | Jun 23, 2023 | Lung Cancer |
Owlstone Medical announced new data on the development of a breath biopsy screening test for the early detection of lung cancer.
Read MorePosted by Melanie Hamilton-Basich | May 30, 2023 | Lung Cancer |
The first-generation lung cancer classification model based on gene expression data is already available for use within Qlucore Insights.
Read MorePosted by Chris Wolski | Apr 18, 2023 | Lung Cancer |
New data demonstrates Exai Bio’s novel RNA- and AI-based platform detected non-small cell lung cancer with high accuracy.
Read More